Status:
ACTIVE_NOT_RECRUITING
National Acalabrutinib Observational Study
Lead Sponsor:
AstraZeneca
Conditions:
Chronic Lymphocytic Leukemia
Eligibility:
All Genders
18+ years
Brief Summary
The efficacy and safety of acalabrutinib in the treatment of patients with chronic lymphocytic leukemia (CLL) have been well established through 3 phase III clinical trials (ELEVATE TN, ASCEND, ELEVAT...
Eligibility Criteria
Inclusion
- Male or female patients aged ≥ 18 years old,
- CLL patients initiated with acalabrutinib at their physician's discretion between January 1st 2021 and December 31st 2022,
- Patients alive at study initiation and who have been informed verbally and/or in writing about this study, and who do not object to their data being electronically processed or subjected to data quality control (certified by physician); or patient who died before study initiation and who did not object to data collection for research purpose(s) during his or her lifetime.
Exclusion
- Patients participating in a clinical trial with an investigational drug within 30 days prior to acalabrutinib initiation,
- Patients who initiated acalabrutinib treatment before January 1st 2021.
Key Trial Info
Start Date :
September 13 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
November 15 2026
Estimated Enrollment :
350 Patients enrolled
Trial Details
Trial ID
NCT05437250
Start Date
September 13 2022
End Date
November 15 2026
Last Update
December 3 2025
Active Locations (61)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Aix-en-Provence, France
2
Research Site
Amiens, France
3
Research Site
Angers, France
4
Research Site
Ars-Laquenexy, France